Eli Lilly (LLY) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $1.6.
- Eli Lilly's Debt to Equity fell 3205.18% to $1.6 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6, marking a year-over-year decrease of 3205.18%. This contributed to the annual value of $1.6 for FY2025, which is 3205.18% down from last year.
- Eli Lilly's Debt to Equity amounted to $1.6 in Q4 2025, which was down 3205.18% from $1.78 recorded in Q3 2025.
- In the past 5 years, Eli Lilly's Debt to Equity ranged from a high of $2.48 in Q2 2021 and a low of $1.51 during Q4 2022
- For the 5-year period, Eli Lilly's Debt to Equity averaged around $1.98, with its median value being $1.99 (2024).
- Per our database at Business Quant, Eli Lilly's Debt to Equity plummeted by 5764.57% in 2021 and then soared by 5407.9% in 2023.
- Over the past 5 years, Eli Lilly's Debt to Equity (Quarter) stood at $1.84 in 2021, then fell by 18.29% to $1.51 in 2022, then skyrocketed by 54.08% to $2.32 in 2023, then rose by 1.52% to $2.36 in 2024, then tumbled by 32.05% to $1.6 in 2025.
- Its last three reported values are $1.6 in Q4 2025, $1.78 for Q3 2025, and $2.17 during Q2 2025.